Keros Therapeutics, Inc. (KROS) Insider Ownership

Historic Insider Ownership Trends

As of March 23, 2026, the three largest insider holders of KROS are Ran Nussbaum (Director, 1.23Mn shares), Tomer Kariv (Director, 1.23Mn shares), Jasbir Seehra (Chief Executive Officer, 385.71K shares).

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares (Direct) Shares (Indirect) Report Date
Ran Nussbaum 0 1,226,412 30 Nov, 2022
Tomer Kariv 0 1,226,412 30 Nov, 2022
Jasbir Seehra Chief Executive Officer 385,708 0 20 Feb, 2026
Julius Knowles 0 102,233 18 Dec, 2025
Jennifer Lachey Chief Scientific Officer 95,100 0 19 Jul, 2022
Christopher Rovaldi Chief Operating Officer 60,000 0 19 Feb, 2025
Advisors Llc Orbimed 0 45,057 18 Dec, 2025
Yung H. Chyung Chief Medical Officer 44,000 0 19 Feb, 2025
Esther Cho Svp, General Counsel 39,755 0 20 Feb, 2026
Keith Regnante Chief Financial Officer 39,261 0 20 Feb, 2026
Lorena Raquel Lerner Chief Science Officer 31,127 0 20 Feb, 2026
Charles W. Newton 13,215 0 11 Mar, 2026
Jean Jacques Bienaime 7,450 0 11 Mar, 2026
Julius Knowles 6,441 0 06 Jun, 2025
Alpna Seth 5,250 0 06 Jun, 2025
Ran Nussbaum 5,250 0 06 Jun, 2025
Nima Farzan 5,250 0 06 Jun, 2025
Tomer Kariv 5,250 0 06 Jun, 2025

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
09 Mar, 2026 Charles W. Newton Common Stock A 13,215 $0.00 13,215 D A
09 Mar, 2026 Jean Jacques Bienaime Common Stock A 2,000 $11.21 7,450 D P
09 Mar, 2026 Charles W. Newton Stock Option (Right to Buy) A 14,788 $0.00 14,788 D A
24 Feb, 2026 Jasbir Seehra Employee Stock Option (Right to Buy) A 217,000 $0.00 217,000 D A
24 Feb, 2026 Esther Cho Employee Stock Option (Right to Buy) A 80,000 $0.00 80,000 D A
24 Feb, 2026 Keith Regnante Employee Stock Option (Right to Buy) A 60,000 $0.00 60,000 D A
24 Feb, 2026 Lorena Raquel Lerner Employee Stock Option (Right to Buy) A 75,000 $0.00 75,000 D A
24 Feb, 2026 Jasbir Seehra Employee Stock Option (right to buy) A 100,000 $0.00 100,000 D A
18 Feb, 2026 Lorena Raquel Lerner Common Stock D 3,873 $16.35 31,127 D S
19 Feb, 2026 Jasbir Seehra Common Stock D 7,015 $16.17 385,708 D S
18 Feb, 2026 Keith Regnante Common Stock D 4,739 $16.35 39,261 D S
18 Feb, 2026 Esther Cho Common Stock D 4,745 $16.35 39,755 D S
07 Jan, 2026 Jasbir Seehra Employee Stock Option (right to buy) A 62,500 $0.00 62,500 D A
21 Nov, 2025 Julius Knowles Common Stock D 191,527 $17.75 150,047 I D
21 Nov, 2025 Advisors Llc Orbimed Common Stock D 140,057 $17.75 759,155 I D
21 Nov, 2025 Julius Knowles Common Stock D 130,494 $17.75 102,233 I D
21 Nov, 2025 Advisors Llc Orbimed Common Stock D 74,465 $17.75 45,057 I D
15 Oct, 2025 Management 4 G.P. (2015) Ltd. Pontifax Common Stock, $0.0001 par value per share D 2,284,612 $17.75 0 I S
15 Oct, 2025 Management 4 G.P. (2015) Ltd. Pontifax Common Stock, $0.0001 par value per share D 1,121,045 $17.75 0 I S
15 Oct, 2025 Management 4 G.P. (2015) Ltd. Pontifax Common Stock, $0.0001 par value per share D 1,226,412 $17.75 0 I S